anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg/d
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2018 06 07;378(23):2191-2201 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, embolic, undetermined source The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg/d
As Treatment, Chronic
Is worse Than
aspirin 100 mg/d
To reduce at 11 months recurrent (ischemic or hemorrhagic) stroke (5% both Tts) while increasing major bleeding (2% rivarox VS 1% aspirin)